Cell therapy weekly: fourth death reported in gene therapy trial for patients with X-linked myotubular myopathy

This week: a fourth patient death has been reported in a gene therapy trial for patients with X-linked myotubular myopathy, positive interim results have been reported for a multi-cell therapy candidate for patients diagnosed with chronic limb-threatening ischemia, and AbbVie and REGENXBIO form a strategic partnership to develop and commercialize a one-time gene therapy for the treatment of wet age-related macular degeneration and other chronic retinal diseases. The news highlights: Fourth death reported in gene therapy trial for patients with X-linked myotubular myopathy Positive data reported for Ixaka’s lead multi-cell therapy candidate REX-001 AbbVie and REGENXBIO form strategic partnership combining...